A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of Zanubrutinib (BGB-3111), a BTK Inhibitor, Plus Tislelizumab (BGB-A317), a PD1 Inhibitor, for Treatment of Patients With Richter Transformation With or Without Sonrotoclax（BGB-11417), a Bcl-2 Inhibitor (CLL-RT1-trial of the GCLLSG).
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 83
- 试验地点
- 22
- 主要终点
- Overall response rate (ORR) after induction therapy according to the refined Lugano Classification (Cheson et al, 2016)
研究概览
简要总结
The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation
详细描述
Richter Transformation (RT) remains one of the biggest challenges in the treatment and management of CLL. While considerable progress has been made in the treatment of CLL, the prognosis of CLL patients with malignant disease transformation still is very poor and reported median OS is between 6 to 8 months. Conventional approaches with chemo- and chemoimmunotherapy have largely failed to improve response rates in RT patients. However, as the established treatment approach for de-novo Diffuse Large B Cell Lymphoma (DLBCL) is chemoimmunotherapy with a combination of Rituximab, Cyclophosphamid, Hydroxydaunorubicin, Vincristin and Prednisolon (R-CHOP), this has become the most commonly used regimen for lack of alternative strategies, despite poor efficacy. Patients being fit enough for allogeneic transplantation are undergoing this procedure after induction with R-CHOP. However, the majority of patients are not suitable for transplantation and relapse quickly. Hence, there is urgent need to improve therapy of RT by testing new compounds and combinations for treatment of this disease. Based on the available preclinical and preliminary clinical data on checkpoint inhibition plus Bruton's tyrosine (BTK) inhibition, the current trial will systematically assess the safety and toxicity of tislelizumab, a programmed cell death protein 1 (PD-1) inhibitor, plus zanubrutinib, a BTK inhibitor in patients with RT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of CLL according to iwCLL criteria (Hallek et al, 2018)
- •Confirmed histopathological diagnosis of RT (diffuse large B-cell lymphoma or Hodgkin's lymphoma [Hodgkin's lymphoma only when not eligible for more in-tensive treatment])
- •Previously untreated RT or patients with objective response or non-tolerance to first-line RT treatment
- •Adequate bone marrow function as defined by:
- •Absolute neutrophil count (ANC) ≥ 1000/mm3, except for patients with bone marrow involvement in which ANC must be ≥ 500/mm3
- •Platelet ≥ 75,000/mm3, except for patients with bone marrow involvement in which the platelet count must be ≥ 30,000/mm3
- •Creatinine clearance ≥30ml/min calculated according to the modified formula of Cockcroft and Gault or directly measured with 24hr urine collection or an equivalent method.
- •Adequate liver function as indicated by a total bilirubin≤ 2 x, AST/ALT ≤ 2.5 x the institutional ULN value, unless directly attributable to the patient's CLL/RT or to Gilbert's Syndrome, in which case a max. total bilirubin ≤ 3 x and AST/ALT ≤ 5 x the institutional ULN value are required.
- •Negative serological testing for hepatitis B (HBsAg negative and anti-HBc nega-tive; patients positive for anti-HBc may be included if PCR for HBV DNA is negative and HBV-DNA PCR is performed every two months until 2 months af-ter last dose of zanubrutinib), negative testing for hepatitis-C RNA and negative HIV test within 6 weeks prior to registration
- •Age at least 18 years
- •ECOG performance status 0-2, ECOG 3 is only permitted if related to CLL or RT (e.g. due to anaemia or severe constitutional symptoms)
- •Life expectancy ≥ 3 months
- •Ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements
排除标准
- •Patients who did not respond to previous line of RT therapy (i.e. primary progressive patients)
- •Patients with more than one prior line of RT therapy
- •Allogenic stem cell transplantation within the last 100 days or signs of active GVHD after prior allogeneic stem cell transplantation within any time
- •Patients with confirmed PML
- •Uncontrolled autoimmune condition
- •Malignancies other than CLL currently requiring systemic therapies (unless the malignant disease is in a stable remission at the discretion of the treating phy-sician)
- •Uncontrolled infection currently requiring systemic treatment
- •Any comorbidity or organ system impairment rated with a CIRS (cumulative ill-ness rating scale) score of 4, excluding the eyes/ears/nose/throat/larynx organ system , or any other life-threatening illness, medical condition or organ system dysfunction that - in the investigator´s opinion could comprise the patients safety or interfere with the absorption or metabolism of the study drugs
- •Requirement of therapy with strong CYP3A4 inhibitors/ inducers
- •Requirement of therapy with phenprocoumon or other vitamin K antagonists.
- •Known active infection with HIV, or serologic status reflecting active hepatitis B or C infection as follows:
- •Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core anti-body (HBcAb). Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B virus (HBV) DNA is undetectable (< 20 IU), and if they are willing to undergo monitoring every 4 weeks for HBV reactivation.
- •Presence of hepatitis C virus (HCV) antibody. Patients with presence of HCV antibody are eligible if HCV RNA is undetectable.
- •Major surgery within 4 weeks of the first dose of study drug.
- •Any uncontrolled or clinically significant cardiovascular disease including the following:
- •Myocardial infarction within 6 months before screening
- •Unstable angina within 3 months before screening
- •New York Heart Association class III or IV congestive heart failure
- •History of clinically significant arrhythmias (eg, sustained ventricular tachy-cardia, ventricular fibrillation, torsades de pointes)
- •History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood trans-fusion or other medical intervention
- •History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
- •Severe or debilitating pulmonary disease
- •Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
- •Use of investigational agents, e.g. monoclonal antibodies or other experimental drugs within clinical trials, which might interfere with the study drug within 28 days (or 5 times half-life [t1/2] of the compound, whichever is longer) prior to registration
- •Known hypersensitivity to tislelizumab, zanubrutinib, sonrotoclax or any of the excipients
- •Pregnant women and nursing mothers (a negative pregnancy test is required for all women of childbearing potential within 7 days before start of treatment)
- •Fertile men or women of childbearing potential unless:
- •surgically sterile or ≥ 2 years after the onset of menopause, or
- •willing to use two methods of reliable contraception including one highly ef-fective contraceptive method (Pearl Index <1) and one additional effective (barrier) method during study treatment and for 6 months after the end of study treatment.
- •Vaccination with a live vaccine <28 days prior to randomization
- •Legal incapacity
- •Prisoners or subjects who are institutionalized by regulatory or court order
- •Persons who are in dependence to the sponsor or an investigator
研究组 & 干预措施
Tislelizumab + Zanubrutinib + Sonrotoclax
Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib + Sonrotoclax
Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib + Sonrotoclax
Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) + Sonrotoclax until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation
干预措施: Zanubrutinib (Drug)
Tislelizumab + Zanubrutinib + Sonrotoclax
Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib + Sonrotoclax
Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib + Sonrotoclax
Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) + Sonrotoclax until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation
干预措施: Sonrotoclax (Drug)
Tislelizumab + Zanubrutinib + Sonrotoclax
Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib + Sonrotoclax
Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib + Sonrotoclax
Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) + Sonrotoclax until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation
干预措施: Tislelizumab (Biological)
Tislelizumab + Zanubrutinib
Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib
Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib
Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation
干预措施: Zanubrutinib (Drug)
Tislelizumab + Zanubrutinib
Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib
Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib
Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation
干预措施: Tislelizumab (Biological)
结局指标
主要结局
Overall response rate (ORR) after induction therapy according to the refined Lugano Classification (Cheson et al, 2016)
时间窗: 18 weeks
Proportion of patients having achieved complete response (CR) or partial response (PR)
次要结局
- ORR after induction therapy according to the IWCLL criteria (Hallek et al, 2018)(18 weeks)
- ORR after consolidation therapy(36 weeks)
- Overall Survival (OS)(Up to 15 months)
- Type, frequency, severity of adverse events (AEs)(Up to 15 months)
- Time to Next Treatment (TTNT)(Up to 15 months)
- Duration of response(Up to 15 months)
- Progression-free Survival (PFS)(Up to 15 months)